Screener
Krystal Biotech, Inc. KRYS Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands) | Three Months Ended / March 31, 2026 | March 31, 2025 |
|---|---|---|
| KB803 | 1,142 | 486 |
| Other research programs | 736 | 692 |
| Other research and development costs (1) | 7,787 | 6,997 |
| Total research and development | 15,331 | 14,256 |
| Selling, general and administrative | 41,014 | 32,647 |
| Income from operations | $53,689 | $36,252 |
| Other income | ||
| Interest and other income, net | 7,753 | 7,345 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s business segments — R&D?
- Krystal Biotech, Inc. (KRYS) reported business segments — R&D of $15.33M in Q1 2026.
- How has Krystal Biotech, Inc.'s business segments — R&D changed year-over-year?
- Krystal Biotech, Inc.'s business segments — R&D increased by 7.5% year-over-year, from $14.26M to $15.33M.
- What is the long-term trend for Krystal Biotech, Inc.'s business segments — R&D?
- Over 3 years (2022 to 2025), Krystal Biotech, Inc.'s business segments — R&D has grown at a 11.0% compound annual growth rate (CAGR), from $42.46M to $58.05M.
- What does business segments — R&D mean?
- Research and development expenses represent the costs incurred by the segment to discover, develop, and test new therapeutic candidates or platform technologies. These investments are critical for long-term growth and pipeline expansion in the biotechnology sector.
Ask your AI about Krystal Biotech, Inc.'s business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude